Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nal-IRI + Pembrolizumab for TNBC with Brain Metastases
NCT05255666Phase 2Withdrawn
- Sponsor
- Washington University School of Medicine
- Start
- Jul 2023
- Primary completion
- Jan 2027
- Modality
- Lipid-based Nanoparticles, Small Molecules
01
Overview
A Phase 2 trial of nanoliposomal irinotecan in triple-negative breast cancer (TNBC), brain metastases, sponsored by Washington University School of Medicine. Planned start Jul 2023; status: withdrawn.
02
Drugs
nanoliposomal irinotecan
03
Conditions
triple-negative breast cancer (TNBC)brain metastases
Beyond the preview
Go deeper on NCT05255666.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05255666.